Table 1.
Biological process | VEGF inhibition | Rho/ROCK inhibition |
---|---|---|
Ischemia | Possible induction of ischemia [24] | Vascular normalization via pericyte coverage [45]; vessel dilation [58]; increased blood velocity and retinal blood flow [59] |
Angiogenesis | Antiangiogenesis [81, 82] | Antiendothelial proliferation in vitro [44, 45]; antiendothelial migration in vitro [44, 45]; antiangiogenesis in vivo retina [43, 45]; antiangiogenesis in vivo choroid [63, 66] |
Hyperpermeability | Antipermeability [83, 84] | Antipermeability in choroidal neovascularization [63, 66] |
Inflammation | Antileukocyte trafficking [81]; antileukostasis [84] | Antileukostasis [38]; anti-M2 macrophage [63] |
Membrane contraction | Possible induction of membrane contraction and tractional retinal detachment [23]; vessel contraction [25] |
Inhibition of membrane contraction in vivo [50, 73]; reduced collagen synthesis in RPE [66]; inhibition of gel contraction by RPE [72, 73]; anti-RPE proliferation [72]; actin depolymerization in RPE [74] |
Neuronal damage | Possible induction of photoreceptor damage [85, 86] | Neuroprotection of RGC [78, 87, 88] |
Fibrosis | Risk of inducible fibrosis [22, 65] | Antifibrosis in choroidal neovascularization [66] |